RxDoctor Payments Data

Carmen Wilson, PA

Physician Assistant · Saint Louis, MONPI 1780715896

Payments from drug & device makers

$1,667in general payments, 2019–2025

Across 20 payments — averaging $83.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$567
  • Janssen Scientific Affairs, LLC$393
  • Legend Biotech USA Inc.$187
  • Incyte Corporation$98
  • Astellas Pharma US Inc$95
  • Karyopharm Therapeutics Inc.$93
  • plus $234 from 6 others

What the payments were for

  • Consulting fees$1157%
  • Food & beverage$1,30378%
  • Education$25015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,667 in reported general payments places this provider in the 80th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$51,851
Medicare patients
156
Services billed
2,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax30$318,802
XareltoRivaroxaban15$17,538
EliquisApixaban14$9,528
ShingrixVaricella-Zoster Ge/As01b/Pf17$3,292
ValacyclovirValacyclovir Hcl83$3,157
IpolPoliomyelitis Vaccine, Killed24$2,110
Dexamethasone56$870
Hydroxyurea24$799
Acyclovir40$652
Boostrix TdapDiphth,pertuss(Acell),tet Vac13$602
Fluconazole11$556
ActhibHaemoph B Poly Conj-Tet Tox/Pf29$361
Infanrix DtapDiph,pertuss(Acell),tet Ped/Pf12$330
Prochlorperazine Maleate12$290
Ciprofloxacin Hcl11$280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$74$318,80230 claims
Johnson & JohnsonXarelto$567$17,53815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →